Sanofi operates a complex global biopharmaceutical model that is currently undergoing an aggressive, profound structural transformation. Historically operating as a diversified healthcare conglomerate selling heavily commoditized diabetes pills Sanofi is pivoting entirely into a specialized, high-margin biotechnology titan. The primary financial engine, generating astronomical, lucrative cash flow, is 'Specialty Care'—dominated by the multi-billion-dollar global sales of the Dupixent megablockbuster (used for severe asthma and eczema). To fund the expensive, risky R&D required to discover the next generation of complex immunology therapies, Sanofi relies on its 'Vaccines' division, an entrenched, reliable global manufacturing network that secures multi-year government contracts for hundreds of millions of flu and polio shots. Finally, in a ruthless, strategic move Sanofi is spinning off its stable but low-margin Consumer Healthcare division (Opella), redirecting all capital strictly into high-risk, high-reward biological specialty medicines. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity. Yes.